中证智能财讯明德生物（002932）1月21日公告，公司作为有限合伙人，以自有资金出资3000万元参与 投资武汉泽森聚芯贰号创业投资合伙企业（有限合伙）。该基金总规模为9500万元，已完成工商注册登 记，公司持股比例为31.5789%，不参与基金投资项目的具体决策。 公告显示，该基金主要投资于光互联、半导体等人工智能基础设施/终端产业链的未上市企业股权。 公司表示，此次与专业投资机构合作，旨在借助其资源及管理能力，完善公司投资布局，分享新兴赛道 成长红利，获取财务投资收益，符合公司战略发展需求。本次投资全部使用自有资金。 明德生物主要从事体外诊断试剂和诊断仪器的研发、生产、销售和服务。2025年前三季度，公司实现营 业总收入2.27亿元，同比增长0.53%。 ...

Core Viewpoint - Mingde Biological's stock price has shown fluctuations, with a year-to-date increase of 11.37% but a recent decline over various trading periods, indicating potential volatility in the market [1][2]. Company Overview - Mingde Biological, established on January 28, 2008, and listed on July 10, 2018, is located in Wuhan, Hubei Province. The company specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments [1]. - The company's revenue composition includes 65.04% from in vitro diagnostic products and solutions, 21.91% from third-party medical testing, and 13.05% from agency business and others [1]. Financial Performance - For the period from January to September 2025, Mingde Biological reported a revenue of 227 million yuan, reflecting a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased by 83.30% to 13.52 million yuan [2]. - Since its A-share listing, the company has distributed a total of 1.76 billion yuan in dividends, with 875 million yuan distributed over the past three years [3]. Shareholder Information - As of November 20, 2025, the number of shareholders for Mingde Biological was 23,400, showing a slight increase of 0.11%. The average number of circulating shares per person decreased by 0.11% to 6,660 shares [2]. - Notable institutional shareholders include Guangfa Value Core Mixed A, holding 2.8462 million shares, and new entrants like Rongtong China Wind 1 and Rongtong Health Industry Flexible Allocation Mixed A/B [3].

Core Viewpoint - Mingde Biological's stock has shown a mixed performance in recent trading sessions, with a year-to-date increase of 14.50% and a notable decline of 8.77% over the past 60 days [1] Financial Performance - For the period from January to September 2025, Mingde Biological reported revenue of 227 million yuan, reflecting a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased significantly by 83.30% to 13.52 million yuan [2] - Cumulatively, since its A-share listing, Mingde Biological has distributed a total of 1.76 billion yuan in dividends, with 875 million yuan distributed over the past three years [3] Shareholder Structure - As of October 31, 2025, the number of shareholders for Mingde Biological decreased by 2.27% to 23,100, while the average number of circulating shares per person increased by 2.32% to 6,763 shares [2] - The top ten circulating shareholders include notable funds such as GF Value Core Mixed A and Rongtong China Wind 1, with some new entrants and changes in holdings among the top shareholders [3] Market Activity - On November 12, Mingde Biological's stock price rose by 2.01% to 19.77 yuan per share, with a trading volume of 39.1 million yuan and a turnover rate of 1.28% [1] - The stock experienced a net outflow of 204,300 yuan from major funds, while large orders showed mixed buying and selling activity [1] Business Overview - Mingde Biological, established on January 28, 2008, specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, with a revenue composition of 65.04% from in vitro diagnostic products, 21.91% from third-party medical testing, and 13.05% from agency and other businesses [1] - The company operates within the pharmaceutical and biological industry, specifically in the medical device and in vitro diagnostic sectors [1]